Lack of effect of lowering LDL cholesterol on cancer: Meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy

PLoS ONE

Volumn 7, Issue 1, 2012, Pages

  Emberson, Jonathan R ^a,l   Kearney, P M ^l   Blackwell, L ^l   Newman, C ^l   Reith, C ^l   Bhala, N ^l   Holland, L ^l   Peto, R ^l   Keech, A ^l   Collins, R ^l   Simes, J ^l   Baigent, C ^l   De Lemos, J ^l   Braunwald, E ^l   Blazing, M ^l   Murphy, S ^l   Downs, J R ^l   Gotto, A ^l   Clearfield, M ^l   Holdaas, H ^l   Gordon, D ^l   Davis, B ^l   Koren, M ^l   Dahlof, B ^l   Poulter, N ^l   Sever, P ^l   Knopp, R H ^l   Fellstrom B ^l   Jardine, A ^l   Schmieder, R ^l   Zannad, F ^l   Goldbourt, U ^l   Kaplinsky, E ^l   Colhoun, H M ^l   Betteridge, D J ^l   Durrington, P N ^l   Hitman, G A ^l   Fuller, J ^l   Neil, A ^l   Wanner, C ^l   Krane, V ^l   Sacks, F ^l   Moye L ^l   Pfeffer, M ^l   Hawkins, C M ^l   Kjekshus, J ^l   Wedel, H ^l   Wikstrand, J ^l   Tavazzi, L ^l   Maggioni, A ^l   Marchioli, R ^l   Tognoni, G ^l   Franzosi, M G ^l   Armitage, J ^l   Parish, S ^l   Sleight, P ^l   Pedersen, T R ^l   Ridker, P M ^l   MacMahon, S ^l   Marschner, I ^l   Tonkin, A ^l   Shaw, J ^l   Serruys, P W ^l   Nakamura, H ^l   Knatterud, G ^l   Furberg, C ^l   Byington, R ^l   Macfarlane, P ^l   Cobbe, S ^l   Ford, I ^l   Murphy, M ^l   Blauw, G J ^l   Packard, C ^l   Shepherd, J ^l   Wilhelmsen, L ^l   Cannon, C ^l   Bowman, L ^l   La Rosa, J ^l   Flather, M ^l   Kastelein, J ^l   Shear, C ^l   Tobert, J ^l   Varigos, J ^l   White, H ^l   Yusuf, S ^l   Baxter, A ^l   Barnes, E H ^l   Buck, G ^l   Herrington, W G ^l   Kirby, A ^l   Lewis, D A ^l   Mellies, M ^e   McGovern, M ^e   Barclay, J ^e   Belder, R ^e   Mitchell, Y ^f   Musliner, T ^f   Ansquer, J C ^g   Llewellyn, M ^h   Bortolini, M ⁱ   Bryzinski, B ^j   Olsson, G ^j   Pears, J ^j   DeMicco, D ^k   more..

^a CLINICAL TRIAL SERVICE UNIT   (United Kingdom)

^b UNIVERSITY COLLEGE CORK   (Ireland)

^c NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF SYDNEY   (Australia)

^e BRISTOL MYERS SQUIBB   (United States)

^f MERCK RESEARCH LABORATORIES   (United States)

^g Laboratoires Fournier   (United States)

^h BAYER CORPORATION   (United States)

ⁱ Novartis Pharma   (Switzerland)

^j ASTRAZENECA R AND D   (Sweden)

^k PFIZER INC   (United States)

^l NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; DIGESTIVE SYSTEM CANCER; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERCHOLESTEROLEMIA; MALIGNANT NEOPLASTIC DISEASE; MEDICAL RECORD REVIEW; MELANOMA; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT CANCER; TREATMENT DURATION; UROGENITAL TRACT CANCER;

EID: 84930670749     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0029849     Document Type: Article

References (30)

1. Cholesterol Treatment Trialists Collaboration (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366: 1267-78.
2. Cholesterol Treatment Trialists Collaboration (2010) Efficacy and safety of more intensive lowering of LDL cholesterol: meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376: 1670-81.
3. Jacobs D, Blackburn H, Higgins M, Reed D, Iso H, et al. (1992) Report of the Conference on Low Blood Cholesterol: Mortality Associations. Circulation 86: 1046-60.
4. Law MR, Thompson SG, (1991) Low serum cholesterol and the risk of cancer: an analysis of the published prospective studies. Cancer Causes Control 2: 253-61.
5. Sharp SJ, Pocock SJ, (1997) Time trends in serum cholesterol before cancer death. Epidemiology 8: 132-6.
6. Kuoppala J, Lamminpaa A, Pukkala E, (2008) Statins and cancer: A systematic review and meta-analysis. Eur J Cancer 44: 2122-32.
7. Dale KM, Coleman CI, Henyan NN, Kluger J, White CM, (2006) Statins and cancer risk: a meta-analysis. JAMA 295: 74-80.
8. Browning DR, Martin RM, (2007) Statins and risk of cancer: a systematic review and meta analysis. Int J Cancer 120: 833-43.
9. Bonovas S, Filioussi K, Flordellis CS, Sitaras NM, (2007) Statins and the risk of colorectal cancer: a meta-analysis of 18 studies involving more than 1.5 million patients. J Clin Oncol 25: 3462-8.
10. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, et al. (2002) Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360: 1623-30.
11. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, et al. (1996) The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 335: 1001-9.
12. Kjekshus J, Apetrei E, Barrios V, Bohm M, Cleland JGF, et al. (2007) Rosuvastatin in Older Patients with Systolic Heart Failure. N Engl J Med 357: 2248-61.
13. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, et al. (2004) Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes. N Engl J Med 350: 1495-504.
14. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, et al. (2005) Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease. N Engl J Med 352: 1425-35.
15. Pedersen TR, Faergeman O, Kastelein JJP, Olsson AG, Tikkanen MJ, et al. (2005) High-Dose Atorvastatin vs Usual-Dose Simvastatin for Secondary Prevention After Myocardial Infarction: The IDEAL Study: A Randomized Controlled Trial. JAMA 294: 2437-45.
16. de Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KAA, et al. (2004) Early Intensive vs a Delayed Conservative Simvastatin Strategy in Patients With Acute Coronary Syndromes: Phase Z of the A to Z Trial. JAMA 292: 1307-16.
17. Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group (2010) Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12 064 survivors of myocardial infarction: a double-blind randomised trial. Lancet 376: 1658-69.
18. Cholesterol Treatment Trialists' (CTT) Collaboration (1995) Protocol for a prospective collaborative overview of all current and planned randomized trials of cholesterol treatment regimens. Am J Cardiol 75: 1130-4.
19. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Collaboration (2006) High-Dose Atorvastatin after Stroke or Transient Ischemic Attack. N Engl J Med 355: 549-59.
20. Athyros VG, Papageorgiou AA, Mercouris BR, Athyrou VV, Symeonidis AN, et al. (2002) Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr Med Res Opin 18: 220-8.
21. Alsheikh-Ali AA, Trikalinos TA, Kent DM, Karas RH, (2008) Statins, Low-Density Lipoprotein Cholesterol, and Risk of Cancer. J Am Coll Cardiol 52: 1141-7.
22. Alsheikh-Ali AA, Maddukuri PV, Han H, Karas RH, (2007) Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials. J Am Coll Cardiol 50: 409-18.
23. Collins R, Armitage J, (2002) High-risk elderly patients PROSPER from cholesterol-lowering therapy. Lancet 360: 1618-9.
24. Solomon KR, Freeman MR, (2008) Do the cholesterol-lowering properties of statins affect cancer risk? Trends Endocrinol Metab 19: 113-21.
25. Hippisley-Cox J, Coupland C, (2010) Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. BMJ 340: c2197.
26. Poynter JN, Gruber SB, Higgins PD, Almog R, Bonner JD, et al. (2005) Statins and the risk of colorectal cancer. N Engl J Med 352: 2184-92.
27. Ford I, Murray H, Packard CJ, Shepherd J, Macfarlane PW, et al. (2007) Long-term follow-up of the West of Scotland Coronary Prevention Study. N Engl J Med 357: 1477-86.
28. LIPID Study Group (2002) Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up. Lancet 359: 1379-87.
29. Strandberg TE, Pyorala K, Cook TJ, Wilhelmsen L, Faergeman O, et al. (2004) Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet 364: 771-7.
30. Heart Protection Study Collaborative Group (2011) Effects on 11 year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 6 years in 20536 high-risk individuals. Lancet doi:10.1016/S0140-6736(11)61125-2.